{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:55:22Z","timestamp":1791406522621,"version":"4.3.3"},"reference-count":154,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"crossref","award":["R01HL157535"],"award-info":[{"award-number":["R01HL157535"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["R01DK129793"],"award-info":[{"award-number":["R01DK129793"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Lipoprotein(a) (Lp[a]) was discovered more than six decades ago. Since then, it has evolved from a subject of curious experiments performed by a few scientists to an extensively explored therapeutic target for prevention and management of cardiovascular disease (CVD). This has prompted an intense search for therapies and agents with potent Lp(a)-specific lowering effects on the horizon. Some of these agents are already in clinical trials to clarify whether lowering high Lp(a) levels would result in reductions in CVD events. The road to this point has been filled with many challenges, where landmark genetic discoveries opened new avenues and set the stage for interventions. Although there is no doubt that genetics play a key role in determining Lp(a) level, accumulating evidence also supports a role for some clinical conditions in influencing Lp(a) levels. CKD is a prevalent condition associated with elevated Lp(a) levels. Most available data show that elevated Lp(a) levels predict CVD risk in patients with CKD. Given the growing evidence for a relationship between Lp(a), CVD, and CKD as well as ongoing cardiovascular outcomes trials of Lp(a)-specific agents, we provide an overview of recent evidence on this topic. We focus on recent studies in patients with CKD on treatment modalities affecting Lp(a) level as well as on existing gaps in knowledge and future research directions related to clinical care and CVD risk reduction in patients with CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.0000000968","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T21:00:09Z","timestamp":1764709209000},"page":"1469-1481","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Lipoprotein(a) and CKD"],"prefix":"10.2215","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-6864","authenticated-orcid":false,"given":"Enkhmaa","family":"Byambaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baback","family":"Roshanravan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-1791","authenticated-orcid":false,"given":"Lars","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"10459","key":"B1-20260826","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet."},{"issue":"25","key":"B2-20260826","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic characterization of genetically lowered human lipoprotein(a) levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"B3-20260826","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1172\/JCI113093","article-title":"Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma","volume":"80","author":"Utermann","year":"1987","journal-title":"J Clin Invest."},{"issue":"3","key":"B4-20260826","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/jmp.12160","article-title":"Rhesus monkey (Macaca mulatta) lipoprotein(a) and apolipoprotein(a): high frequency of small size apolipoprotein(a) isoforms","volume":"44","author":"Enkhmaa","year":"2015","journal-title":"J Med Primatol."},{"issue":"10","key":"B5-20260826","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1016\/S0021-9258(18)83643-2","article-title":"Rhesus monkey apolipoprotein(a)","volume":"264","author":"Tomlinson","year":"1989","journal-title":"J Biol Chem."},{"issue":"4932","key":"B6-20260826","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1126\/science.2530631","article-title":"The mysteries of lipoprotein(a)","volume":"246","author":"Utermann","year":"1989","journal-title":"Science."},{"issue":"6144","key":"B7-20260826","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature."},{"issue":"6","key":"B8-20260826","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1172\/JCI115248","article-title":"Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis","volume":"87","author":"Lackner","year":"1991","journal-title":"J Clin Invest."},{"issue":"6","key":"B9-20260826","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF00201550","article-title":"Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups","volume":"86","author":"Sandholzer","year":"1991","journal-title":"Hum Genet."},{"issue":"3","key":"B10-20260826","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF00220066","article-title":"The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration","volume":"90","author":"Kraft","year":"1992","journal-title":"Hum Genet."},{"key":"B11-20260826","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","article-title":"Lipoprotein(a) beyond the Kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene","volume":"349","author":"Coassin","year":"2022","journal-title":"Atherosclerosis."},{"issue":"26","key":"B12-20260826","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med."},{"issue":"3","key":"B13-20260826","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/joim.12207","article-title":"Genetic determination of lipoprotein(a) and its association with cardiovascular disease: convenient does not always mean better","volume":"276","author":"Kronenberg","year":"2014","journal-title":"J Intern Med."},{"issue":"9","key":"B14-20260826","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1161\/ATVBAHA.107.141291","article-title":"A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease","volume":"27","author":"Luke","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"9","key":"B15-20260826","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week","volume":"80","author":"Tsimikas","year":"2022","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"B16-20260826","doi-asserted-by":"crossref","first-page":"e14581","DOI":"10.1371\/journal.pone.0014581","article-title":"Single-nucleotide polymorphisms in LPA explain Most of the ancestry-specific variation in Lp(a) levels in African Americans","volume":"6","author":"Deo","year":"2011","journal-title":"PLoS One."},{"issue":"3","key":"B17-20260826","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1172\/JCI115645","article-title":"Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease","volume":"89","author":"Sandholzer","year":"1992","journal-title":"J Clin Invest."},{"issue":"7","key":"B18-20260826","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by ethnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J Lipid Res."},{"issue":"12","key":"B19-20260826","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/01.ATV.20.12.2619","article-title":"High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men","volume":"20","author":"Paultre","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"2","key":"B20-20260826","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0022-2275(20)30165-6","article-title":"Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians","volume":"43","author":"Rubin","year":"2002","journal-title":"J Lipid Res."},{"issue":"17","key":"B21-20260826","doi-asserted-by":"crossref","first-page":"e020158","DOI":"10.1161\/JAHA.120.020158","article-title":"Lp(a)-associated oxidized phospholipids in healthy Black and white participants in relation to apo(a) size, age, and family structure","volume":"10","author":"Berglund","year":"2021","journal-title":"J Am Heart Assoc."},{"issue":"1","key":"B22-20260826","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"9","key":"B23-20260826","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1194\/jlr.R077693","article-title":"The metabolism of lipoprotein (a): an ever-evolving story","volume":"58","author":"Reyes-Soffer","year":"2017","journal-title":"J Lipid Res."},{"key":"B24-20260826","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2022.04.002","article-title":"Recent advances in demystifying the metabolism of lipoprotein(a)","volume":"349","author":"Chemello","year":"2022","journal-title":"Atherosclerosis."},{"issue":"10","key":"B25-20260826","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J Lipid Res."},{"issue":"10","key":"B26-20260826","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/01.ATV.0000280571.28102.d4","article-title":"New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease","volume":"27","author":"Tsimikas","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"8","key":"B27-20260826","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/ATVBAHA.107.145805","article-title":"Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study","volume":"27","author":"Kiechl","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"1","key":"B28-20260826","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/CIRCRESAHA.116.308811","article-title":"PCSK9 association with lipoprotein(a)","volume":"119","author":"Tavori","year":"2016","journal-title":"Circ Res."},{"issue":"3","key":"B29-20260826","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/ATVBAHA.123.319937","article-title":"Diacylglycerols and lysophosphatidic acid, enriched on lipoprotein(a), contribute to monocyte inflammation","volume":"44","author":"Dzobo","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"3","key":"B30-20260826","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol."},{"issue":"1","key":"B31-20260826","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"issue":"8","key":"B32-20260826","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol."},{"issue":"39","key":"B33-20260826","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J."},{"key":"B34-20260826","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2023.04.012","article-title":"Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society","volume":"374","author":"Kronenberg","year":"2023","journal-title":"Atherosclerosis."},{"key":"B35-20260826","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein(a) measurement issues: are we making a mountain out of a molehill?","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis."},{"issue":"1","key":"B36-20260826","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/0004563220968473","article-title":"Lp(a): when and how to measure it","volume":"58","author":"Cegla","year":"2021","journal-title":"Ann Clin Biochem."},{"issue":"4","key":"B37-20260826","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res."},{"issue":"6","key":"B38-20260826","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.124.069210","article-title":"Lipoprotein(a) as a pharmacological target: premises, promises, and prospects","volume":"151","author":"Greco","year":"2025","journal-title":"Circulation."},{"issue":"10057","key":"B39-20260826","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet."},{"issue":"3","key":"B40-20260826","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med."},{"key":"B41-20260826","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of Lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J."},{"issue":"20","key":"B42-20260826","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med."},{"issue":"21","key":"B43-20260826","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA."},{"issue":"9","key":"B44-20260826","doi-asserted-by":"crossref","first-page":"e70079","DOI":"10.1111\/eci.70079","article-title":"siRNA-based therapeutics for lipoprotein (a) lowering: a path toward precision cardiovascular medicine","volume":"55","author":"Kanbay","year":"2025","journal-title":"Eur J Clin Invest."},{"key":"B45-20260826","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis."},{"issue":"7","key":"B46-20260826","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3390\/nu12072024","article-title":"Diet and Lp(a): does dietary change modify residual cardiovascular risk conferred by Lp(a)?","volume":"12","author":"Enkhmaa","year":"2020","journal-title":"Nutrients."},{"issue":"1","key":"B47-20260826","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ajcnut.2023.05.017","article-title":"Lipoprotein(a) and diet-a challenge for a role of saturated fat in cardiovascular disease risk reduction?","volume":"118","author":"Law","year":"2023","journal-title":"Am J Clin Nutr."},{"issue":"10","key":"B48-20260826","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3390\/nu17101714","article-title":"Lipoprotein(a) and effects of diet: time for reassessment","volume":"17","author":"Enkhmaa","year":"2025","journal-title":"Nutrients."},{"issue":"9","key":"B49-20260826","doi-asserted-by":"crossref","first-page":"100420","DOI":"10.1016\/j.jlr.2023.100420","article-title":"Reducing saturated fat intake lowers LDL-C but increases Lp(a) levels in African Americans: the GET-READI feeding trial","volume":"64","author":"Law","year":"2023","journal-title":"J Lipid Res."},{"issue":"2","key":"B50-20260826","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41591-020-01209-1","article-title":"Effect of a plant-based, low-fat diet versus an animal-based, ketogenic diet on ad libitum energy intake","volume":"27","author":"Hall","year":"2021","journal-title":"Nat Med."},{"issue":"8","key":"B51-20260826","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/clc.23027","article-title":"Consumption of a defined, plant-based diet reduces lipoprotein(a), inflammation, and other atherogenic lipoproteins and particles within 4 weeks","volume":"41","author":"Najjar","year":"2018","journal-title":"Clin Cardiol."},{"issue":"3","key":"B52-20260826","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1161\/01.ATV.0000118012.64932.f4","article-title":"Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a)","volume":"24","author":"Silaste","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"4","key":"B53-20260826","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1365-2796.2011.02383.x","article-title":"Replacing dairy fat with rapeseed oil causes rapid improvement of hyperlipidaemia: a randomized controlled study","volume":"270","author":"Iggman","year":"2011","journal-title":"J Intern Med."},{"issue":"9","key":"B54-20260826","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1161\/01.ATV.17.9.1822","article-title":"Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women","volume":"17","author":"Tuck","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"7","key":"B55-20260826","first-page":"2633","article-title":"Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males","volume":"81","author":"Berglund","year":"1996","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"B56-20260826","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0021-9150(92)90008-5","article-title":"Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid","volume":"92","author":"Crook","year":"1992","journal-title":"Atherosclerosis."},{"issue":"4","key":"B57-20260826","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein(a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J Lipid Res."},{"issue":"2","key":"B58-20260826","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","article-title":"Causes and consequences of lipoprotein(a) abnormalities in kidney disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin Exp Nephrol."},{"issue":"1","key":"B59-20260826","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1681\/ASN.V111105","article-title":"Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure","volume":"11","author":"Kronenberg","year":"2000","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B60-20260826","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0272-6386(99)70147-2","article-title":"Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure","volume":"33","author":"Milionis","year":"1999","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"B61-20260826","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116213","article-title":"Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a)","volume":"91","author":"Dieplinger","year":"1993","journal-title":"J Clin Invest."},{"issue":"1","key":"B62-20260826","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1681\/ASN.V61110","article-title":"Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis","volume":"6","author":"Kronenberg","year":"1995","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B63-20260826","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1046\/j.1523-1755.1999.00273.x","article-title":"Inflammation enhances cardiovascular risk and mortality in hemodialysis patients","volume":"55","author":"Zimmermann","year":"1999","journal-title":"Kidney Int."},{"issue":"2","key":"B64-20260826","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1523-1755.2004.00418.x","article-title":"The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome","volume":"65","author":"Kronenberg","year":"2004","journal-title":"Kidney Int."},{"issue":"2","key":"B65-20260826","first-page":"125","article-title":"Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome","volume":"69","author":"Hong","year":"1995","journal-title":"Nephron."},{"issue":"6 Pt 1","key":"B66-20260826","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/clinchem\/41.6.908","article-title":"Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relation to remission of proteinuria","volume":"41","author":"Joven","year":"1995","journal-title":"Clin Chem."},{"issue":"8","key":"B67-20260826","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.V981474","article-title":"Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome","volume":"9","author":"De Sain-Van Der Velden","year":"1998","journal-title":"J Am Soc Nephrol."},{"issue":"10","key":"B68-20260826","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/sj.ki.5002131","article-title":"In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients","volume":"71","author":"Frischmann","year":"2007","journal-title":"Kidney Int."},{"issue":"9","key":"B69-20260826","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.ejhg.5201016","article-title":"Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation","volume":"11","author":"Kronenberg","year":"2003","journal-title":"Eur J Hum Genet."},{"issue":"2","key":"B70-20260826","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0021-9150(99)00014-3","article-title":"Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up","volume":"144","author":"Kerschdorfer","year":"1999","journal-title":"Atherosclerosis."},{"issue":"3","key":"B71-20260826","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000112225","article-title":"Effects of renal replacement therapy on plasma lipoprotein(a) levels","volume":"28","author":"Rosas","year":"2008","journal-title":"Am J Nephrol."},{"issue":"6","key":"B72-20260826","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000168361","article-title":"Elevated lipoprotein(a) levels in renal transplantation and hemodialysis patients","volume":"11","author":"Heimann","year":"1991","journal-title":"Am J Nephrol."},{"issue":"3","key":"B73-20260826","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1445-5994.1992.tb02119.x","article-title":"Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation","volume":"22","author":"Irish","year":"1992","journal-title":"Aust N Z J Med."},{"issue":"5","key":"B74-20260826","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.V1251052","article-title":"Impact of apolipoprotein(a) phenotypes on long-term renal transplant survival","volume":"12","author":"Wahn","year":"2001","journal-title":"J Am Soc Nephrol."},{"issue":"10","key":"B75-20260826","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1194\/jlr.RA120000771","article-title":"Serum lipoprotein (a) associates with a higher risk of reduced renal function: a prospective investigation","volume":"61","author":"Xuan","year":"2020","journal-title":"J Lipid Res."},{"issue":"7","key":"B76-20260826","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.xkme.2023.100648","article-title":"Lipoprotein(a) and the risk for recurrent atherosclerotic cardiovascular events among adults with CKD: the Chronic Renal Insufficiency Cohort (CRIC) study","volume":"5","author":"Poudel","year":"2023","journal-title":"Kidney Med."},{"issue":"1","key":"B77-20260826","doi-asserted-by":"crossref","first-page":"108378","DOI":"10.1016\/j.jdiacomp.2022.108378","article-title":"Study on the relationship between lipoprotein (a) and diabetic kidney disease","volume":"37","author":"Wang","year":"2023","journal-title":"J Diabetes Complications."},{"issue":"11","key":"B78-20260826","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation."},{"issue":"7","key":"B79-20260826","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2005101085","article-title":"Chronic kidney disease and mortality risk: a systematic review","volume":"17","author":"Tonelli","year":"2006","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B80-20260826","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s40620-023-01590-3","article-title":"Relationship between lipoprotein(a) levels, cardiovascular outcomes and death in patients with chronic kidney disease: a systematic review of prospective studies","volume":"36","author":"Barbagelata","year":"2023","journal-title":"J Nephrol."},{"issue":"4","key":"B81-20260826","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/089686080202200408","article-title":"Apolipoprotein(a) phenotype and lipoprotein(a) level predict peritoneal dialysis patient mortality","volume":"22","author":"Iliescu","year":"2002","journal-title":"Perit Dial Int."},{"issue":"10","key":"B82-20260826","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1161\/ATVBAHA.117.309920","article-title":"Lipoprotein(a) and risk of myocardial infarction and death in chronic kidney disease: findings from the CRIC study (Chronic Renal Insufficiency Cohort)","volume":"37","author":"Bajaj","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"6","key":"B83-20260826","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/joim.20027","article-title":"Lipoprotein(a) concentrations and cardiovascular disease in patients with chronic kidney disease: results from the German chronic kidney disease study","volume":"296","author":"Gruber","year":"2024","journal-title":"J Intern Med."},{"issue":"7","key":"B84-20260826","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol."},{"issue":"5","key":"B85-20260826","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jacc.2021.05.037","article-title":"Frequent LPA KIV-2 variants lower lipoprotein(a) concentrations and protect against coronary artery disease","volume":"78","author":"Schachtl-Riess","year":"2021","journal-title":"J Am Coll Cardiol."},{"issue":"23","key":"B86-20260826","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/eurheartj\/ehx174","article-title":"A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction","volume":"38","author":"Coassin","year":"2017","journal-title":"Eur Heart J."},{"issue":"1","key":"B87-20260826","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13073-020-00771-0","article-title":"Investigation of a nonsense mutation located in the complex KIV-2 copy number variation region of apolipoprotein(a) in 10,910 individuals","volume":"12","author":"Di Maio","year":"2020","journal-title":"Genome Med."},{"issue":"5","key":"B88-20260826","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/ki.1993.357","article-title":"Lipoprotein(a) in nephrotic syndrome","volume":"44","author":"Stenvinkel","year":"1993","journal-title":"Kidney Int."},{"issue":"6","key":"B89-20260826","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/ije\/dyab203","article-title":"Trans-ethnic Mendelian-randomization study reveals causal relationships between cardiometabolic factors and chronic kidney disease","volume":"50","author":"Zheng","year":"2022","journal-title":"Int J Epidemiol."},{"issue":"2","key":"B90-20260826","doi-asserted-by":"crossref","first-page":"2383727","DOI":"10.1080\/0886022X.2024.2383727","article-title":"Causal effect of lipoprotein(a) level on chronic kidney disease of European ancestry: a two-sample Mendelian randomization study","volume":"46","author":"Zhu","year":"2024","journal-title":"Ren Fail."},{"issue":"5","key":"B91-20260826","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/10408363.2020.1723487","article-title":"Diagnostic utility of protein to creatinine ratio (P\/C ratio) in spot urine sample within routine clinical practice","volume":"57","author":"Kami\u0144ska","year":"2020","journal-title":"Crit Rev Clin Lab Sci."},{"issue":"5","key":"B92-20260826","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1194\/jlr.P052209","article-title":"IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans","volume":"56","author":"M\u00fcller","year":"2015","journal-title":"J Lipid Res."},{"issue":"9","key":"B93-20260826","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1194\/jlr.R053066","article-title":"Current therapies for lowering lipoprotein (a)","volume":"57","author":"van Capelleveen","year":"2016","journal-title":"J Lipid Res."},{"key":"B94-20260826","doi-asserted-by":"crossref","first-page":"105689","DOI":"10.1016\/j.phrs.2021.105689","article-title":"Beyond Lipoprotein(a) plasma measurements: lipoprotein(a) and inflammation","volume":"169","author":"Reyes-Soffer","year":"2021","journal-title":"Pharmacol Res."},{"issue":"4","key":"B95-20260826","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B96-20260826","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.atherosclerosis.2022.04.004","article-title":"Lipoprotein(a): an underestimated inflammatory mastermind","volume":"349","author":"Dzobo","year":"2022","journal-title":"Atherosclerosis."},{"issue":"46","key":"B97-20260826","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1093\/eurheartj\/ehac444","article-title":"Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy","volume":"43","author":"Ridker","year":"2022","journal-title":"Eur Heart J."},{"issue":"8","key":"B98-20260826","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/s41591-024-03043-1","article-title":"IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial","volume":"30","author":"Chertow","year":"2024","journal-title":"Nat Med."},{"issue":"10289","key":"B99-20260826","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet."},{"issue":"11","key":"B100-20260826","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","article-title":"From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?","volume":"117","author":"Ridker","year":"2021","journal-title":"Cardiovasc Res."},{"issue":"3","key":"B101-20260826","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-Based genetic analysis","volume":"83","author":"Bj\u00f6rnson","year":"2024","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"B102-20260826","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet."},{"key":"B103-20260826","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med."},{"issue":"6","key":"B104-20260826","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J."},{"issue":"16","key":"B105-20260826","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med."},{"issue":"12","key":"B106-20260826","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation."},{"issue":"16","key":"B107-20260826","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","article-title":"Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE","volume":"147","author":"Gaba","year":"2023","journal-title":"Circulation."},{"issue":"14","key":"B108-20260826","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med."},{"issue":"4","key":"B109-20260826","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","article-title":"Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis","volume":"157","author":"Palmer","year":"2012","journal-title":"Ann Intern Med."},{"issue":"24","key":"B110-20260826","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J."},{"key":"B111-20260826","doi-asserted-by":"crossref","first-page":"6677012","DOI":"10.1155\/2021\/6677012","article-title":"Association between PCSK9 levels and markers of inflammation, oxidative stress, and endothelial dysfunction in a population of nondialysis chronic kidney disease patients","volume":"2021","author":"Dounousi","year":"2021","journal-title":"Oxid Med Cell Longev."},{"issue":"6","key":"B112-20260826","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","article-title":"PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role","volume":"57","author":"Raal","year":"2016","journal-title":"J Lipid Res."},{"issue":"18","key":"B113-20260826","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","article-title":"Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor","volume":"290","author":"Romagnuolo","year":"2015","journal-title":"J Biol Chem."},{"issue":"7","key":"B114-20260826","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1161\/ATVBAHA.112.250043","article-title":"Proprotein convertase subtilisin\/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor","volume":"32","author":"Sun","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"3","key":"B115-20260826","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0022-2275(20)43165-7","article-title":"Heterogeneity of human lipoprotein Lp[a]: cytochemical and biochemical studies on the interaction of two Lp[a] species with the LDL receptor","volume":"31","author":"Armstrong","year":"1990","journal-title":"J Lipid Res."},{"issue":"2","key":"B116-20260826","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.diabet.2010.08.006","article-title":"Effect of atorvastatin on lipoprotein (a) and interleukin-10: a randomized placebo-controlled trial","volume":"37","author":"Hern\u00e1ndez","year":"2011","journal-title":"Diabetes Metab."},{"issue":"6","key":"B117-20260826","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/j.1552-4604.1993.tb04706.x","article-title":"Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a","volume":"33","author":"Hunninghake","year":"1993","journal-title":"J Clin Pharmacol."},{"issue":"1-3","key":"B118-20260826","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0009-8981(91)90239-9","article-title":"Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor pravastatin: results of a 2-year investigation","volume":"204","author":"Fieseler","year":"1991","journal-title":"Clin Chim Acta."},{"issue":"5","key":"B119-20260826","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/01.CIR.80.5.1313","article-title":"HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels","volume":"80","author":"Kostner","year":"1989","journal-title":"Circulation."},{"issue":"2","key":"B120-20260826","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0021-9150(02)00072-2","article-title":"Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk","volume":"164","author":"Gonbert","year":"2002","journal-title":"Atherosclerosis."},{"issue":"6","key":"B121-20260826","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","article-title":"Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease","volume":"93","author":"Toth","year":"2018","journal-title":"Kidney Int."},{"issue":"1","key":"B122-20260826","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamacardio.2018.4178","article-title":"Interindividual variation in low-density lipoprotein cholesterol level reduction with evolocumab: an analysis of FOURIER trial data","volume":"4","author":"Qamar","year":"2019","journal-title":"JAMA Cardiol."},{"issue":"23","key":"B123-20260826","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol."},{"issue":"10","key":"B124-20260826","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1194\/jlr.M078212","article-title":"The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab","volume":"58","author":"Enkhmaa","year":"2017","journal-title":"J Lipid Res."},{"issue":"24","key":"B125-20260826","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med."},{"issue":"8","key":"B126-20260826","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/CIRCULATIONAHA.110.960138","article-title":"Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"122","author":"Riddle","year":"2010","journal-title":"Circulation."},{"issue":"2","key":"B127-20260826","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med."},{"issue":"22","key":"B128-20260826","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"issue":"7","key":"B129-20260826","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"issue":"4","key":"B130-20260826","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med."},{"issue":"5","key":"B131-20260826","doi-asserted-by":"crossref","first-page":"bvaa037","DOI":"10.1210\/jendso\/bvaa037","article-title":"Glucagon-like Peptide-1 receptor agonists versus sodium-glucose cotransporter inhibitors for treatment of T2DM","volume":"4","author":"McKee","year":"2020","journal-title":"J Endocr Soc."},{"issue":"2","key":"B132-20260826","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10","key":"B133-20260826","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"B134-20260826","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"issue":"14","key":"B135-20260826","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1093\/cvr\/cvad122","article-title":"Genetic variation in solute carrier family 5 member 2 mimicking sodium-glucose co-transporter 2-inhibition and risk of cardiovascular disease and all-cause mortality: reduced risk not explained by lower plasma glucose","volume":"119","author":"Bechmann","year":"2023","journal-title":"Cardiovasc Res."},{"issue":"24","key":"B136-20260826","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"issue":"1","key":"B137-20260826","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12933-022-01676-5","article-title":"Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"21","author":"Zhang","year":"2022","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"B138-20260826","doi-asserted-by":"crossref","first-page":"2418086","DOI":"10.1080\/14017431.2024.2418086","article-title":"Cardiovascular and kidney benefits of SGLT-2is and GLP-1RAs according to baseline blood pressure in type 2 diabetes: a systematic meta-analysis of cardiovascular outcome trials","volume":"58","author":"Kunutsor","year":"2024","journal-title":"Scand Cardiovasc J."},{"issue":"6","key":"B139-20260826","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.pcd.2024.09.007","article-title":"Cardiovascular effectiveness of newer glucose-lowering agents, with and without baseline lipid-lowering therapy in type 2 diabetes: a systematic meta-analysis of cardiovascular outcome trials and real-world evidence","volume":"18","author":"Kunutsor","year":"2024","journal-title":"Prim Care Diabetes."},{"issue":"1","key":"B140-20260826","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1038\/s41598-021-89620-7","article-title":"Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients","volume":"11","author":"Uneda","year":"2021","journal-title":"Sci Rep."},{"issue":"1","key":"B141-20260826","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12944-017-0443-4","article-title":"A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes","volume":"16","author":"Cha","year":"2017","journal-title":"Lipids Health Dis."},{"issue":"1","key":"B142-20260826","doi-asserted-by":"crossref","first-page":"bvz017","DOI":"10.1210\/jendso\/bvz017","article-title":"Effects of dapagliflozin on endothelial dysfunction in type 2 diabetes with established ischemic heart disease (EDIFIED)","volume":"4","author":"Zainordin","year":"2020","journal-title":"J Endocr Soc."},{"key":"B143-20260826","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jacl.2024.12.015","article-title":"Effect of empagliflozin on plasma lipids and lipoproteins in type 2 diabetes and heart failure - empire HF and SIMPLE","volume":"19","author":"Emanuelsson","year":"2025","journal-title":"J Clin Lipidol."},{"issue":"4","key":"B144-20260826","doi-asserted-by":"crossref","first-page":"108436","DOI":"10.1016\/j.jdiacomp.2023.108436","article-title":"The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: a randomized, prospective, intervention study","volume":"37","author":"Bechlioulis","year":"2023","journal-title":"J Diabetes Complications."},{"issue":"12","key":"B145-20260826","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.numecd.2014.06.010","article-title":"Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight\/obese persons with prediabetes","volume":"24","author":"Ariel","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis."},{"issue":"6","key":"B146-20260826","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/medicina60060908","article-title":"Influence of dulaglutide on serum biomarkers of atherosclerotic plaque instability: an interventional analysis of cytokine profiles in diabetic Subjects-A pilot study","volume":"60","author":"Hachu\u0142a","year":"2024","journal-title":"Medicina (Kaunas)."},{"issue":"8","key":"B147-20260826","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1373\/clinchem.2010.146779","article-title":"Lipoprotein(a) and risk of type 2 diabetes","volume":"56","author":"Mora","year":"2010","journal-title":"Clin Chem."},{"key":"B148-20260826","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.atherosclerosis.2022.04.016","article-title":"Lipoprotein (a) and diabetes mellitus","volume":"349","author":"Lamina","year":"2022","journal-title":"Atherosclerosis."},{"issue":"1","key":"B149-20260826","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2337\/db13-1144","article-title":"The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?","volume":"63","author":"Ye","year":"2014","journal-title":"Diabetes."},{"issue":"32","key":"B150-20260826","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","article-title":"Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium","volume":"38","author":"Waldeyer","year":"2017","journal-title":"Eur Heart J."},{"issue":"10","key":"B151-20260826","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.numecd.2018.05.010","article-title":"Elevated lipoprotein (a) levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus","volume":"28","author":"Zhang","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"B152-20260826","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2018.12.022","article-title":"Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: the Atherosclerosis Risk in Communities study","volume":"282","author":"Saeed","year":"2019","journal-title":"Atherosclerosis."},{"issue":"2","key":"B153-20260826","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.2337\/dc19-1117","article-title":"The role of lipoprotein (a) as a marker of residual risk in patients with diabetes and established cardiovascular disease on optimal medical therapy: post hoc analysis of ACCELERATE","volume":"43","author":"Shah","year":"2020","journal-title":"Diabetes Care."},{"key":"B154-20260826","doi-asserted-by":"crossref","first-page":"633529","DOI":"10.3389\/fendo.2021.633529","article-title":"Association between lipoprotein (A) and diabetic nephropathy in patients with type 2 diabetes mellitus: a meta-analysis","volume":"12","author":"Ren","year":"2021","journal-title":"Front Endocrinol (Lausanne)."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:01:35Z","timestamp":1787752895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000968"}},"subtitle":["Insights into New Therapeutic Opportunities"],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":154,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000000968","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]}}}